Opthea Ltd has released a press release.
Opthea Doses First Patient in OPT-302 wAMD Ph2b trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Opthea
- Opthea Granted Key United States Patent Covering OPT-302
- Opthea Appendix 4E and Annual Report 2017
- Opthea Presents Further Positive Data from OPT-302 Ph1/2A
- Opthea Allowed Key Patent for OPT-302 in United States
- Opthea Completes A$45 Million Capital Raising
Later from Opthea
- Opthea Initiates OPT-302 Diabetic Macular Edema Trial
- Opthea Receives A$2.7m R&D Tax Incentive
- Opthea Doses wAMD Patients in Europe and Israel
- Opthea reaches mid-way in recruitment for Ph2b wAMD trial
- Opthea Meets Primary Safety Objective in DME Phase 1b trial
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea